Sacrosidase
Sucraid (sacrosidase) is an enzyme pharmaceutical. Sacrosidase was first approved as Sucraid on 1998-04-09. It is used to treat congenital abnormalities and digestive system diseases in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sucraid
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sacrosidase
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Sucraid | sacrosidase | Qol Medical | N-20772 RX | 1998-04-09 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sucraid | Biologic Licensing Application | 2024-08-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| congenital abnormalities | EFO_0003915 | D000013 | Q89.9 |
| digestive system diseases | HP_0011024 | D004066 | K92.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
sacrosidase, Sucraid, QOL Medical, LLC | |||
| 2105-04-09 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inborn errors carbohydrate metabolism | D002239 | — | — | — | — | — | 2 | — | 2 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 2 | 2 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | — | — | 1 | 1 |
| Colic | D003085 | HP_0011848 | R10.83 | — | — | — | — | 1 | 1 |
| Flatulence | D005414 | — | R14.3 | — | — | — | — | 1 | 1 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 1 | 1 |
| Gastric dilatation | D013271 | — | — | — | — | — | — | 1 | 1 |
| Food intolerance | D000073923 | — | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sacrosidase |
| INN | sacrosidase |
| Description | Sacrosidase (trade name Sucraid) is a medication used to replace sucrase in people lacking this enzyme. It is available as an oral solution. Sucraid is approved by the U.S. Food and Drug Administration (FDA) for the therapy of the genetically determined sucrase deficiency that is part of the Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase assists in the breakdown of sugar/sucrose into simpler forms and is useful for the relief of gastrointestinal symptoms that are associated with CSID.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 85897-35-4 |
| RxCUI | 214817 |
| ChEMBL ID | CHEMBL1201487 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06760 |
| UNII ID | 8A7F670F2Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,913 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
82 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use